
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics is supported by a commercial portfolio with three FDA-approved products, led by ZELSUVI, whose 3Q26 revenue of $15.2M and 12,384 units dispensed show steady demand despite seasonality. Its outlook improves further from the proposed all-stock merger with Castle Creek Biosciences, which adds D-Fi, a Phase III rare-disease asset that could expand the company’s long-term revenue base while remaining aligned with its dermatology focus. Although the transaction increases dilution and R&D spend, the company’s $24M in cash in 2Q26, additional Horizon funding access, and expanding formulary coverage for about 24M lives support commercialization and pipeline execution.
Bears say
Pelthos Therapeutics is facing a weaker-than-expected commercial trajectory, as 3Q26 Zelsuvmi revenue of $15.2M fell short of both OpCo and consensus expectations, while only a 4% scripts increase and higher gross-to-net deductions limited net revenue expansion. The company’s growth profile appears to be flattening over the past 2 quarters, and management’s uncertainty into the holiday slow down suggests additional 4Q26 pressure even with a stronger October and a new PBM agreement. Fundamentally, the negative outlook is driven by dependence on successful Zelsuvmi commercialization, rising GtNs at 31.5% in 3Q26, and key risks around financing, intellectual property, regulatory/reimbursement changes, and competition.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pelthos Therapeutics Inc (PTHS) Forecast
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares